基于mTOR自噬途径宿主导向疗法在抗结核分枝杆菌感染中的研究进展

Progress of host-directed therapy based on mTOR autophagy pathway in anti-mycobacterium tuberculosis infection

由于耐多药或耐利福平结核菌株的出现,研究新型结核治疗方案成为必要。宿主抗结核分枝杆菌(MTB)感染主要依靠细胞免疫实现的,自噬是一种宿主防御的基本途径,哺乳动物雷帕霉素靶蛋白(mTOR)是自噬的主要调节剂,与控制MTB的负荷有关。近年来,研究表明一些药物或小分子物质通过mTOR途径激活自噬的宿主导向疗法可实现减轻宿主体内MTB负荷。故本文就基于mTOR途径宿主导向疗法在抗MTB感染中的研究进展作相应的阐述。

The emergence of multi-drug resistant or rifampin-resistant Mycobacterium tuberculosis(MTB)has highlighted the necessity to develop novel therapeutics.The host′s resistance to MTB infection is mainly achieved by cellular immunity.Autophagy is a basic pathway of host defense,regulated by the mammalian target of rapamycin(mTOR),has been associated with the control of the MTB load.In recent years,study shows that host-directed therapies activate autophagy by some drugs or small molecules through the mTOR pathway can reduce MTB load in the host.In this review,the progress of host-directed therapy is discussed based on mTOR pathway against MTB infection.